Corcept Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Corcept Therapeutics Inc 公司

Corcept Therapeutics Incorporated 是一家商業階段公司，致力於發現和開發通過調節激素皮質醇作用來治療嚴重內分泌、腫瘤、代謝和神經系統疾病的藥物。該公司通過發現、開發和商業化醫藥產品部門開展業務。該公司已在美國銷售 Korlym（米非司酮），用於治療患有庫欣綜合徵的患者。該公司的選擇性皮質醇調節劑產品組合由四個系列組成，共計約 1,000 種化合物。其選擇性皮質醇調節劑產品組合包括 relacorilant、exicorilant、dazucorilant 和 miricorilant。Korlyms 的活性成分米非司酮可減少過量皮質醇與 GR 的結合，它可以調節皮質醇異常水平和釋放模式的影響，而不會損害皮質醇的健康功能和節律。

公司簡介

公司代碼CORT

公司名稱Corcept Therapeutics Inc

上市日期Apr 15, 2004

成立日期1998

CEODr. Joseph K. Belanoff, M.D.

員工數量500

證券類型Ordinary Share

年結日Apr 15

公司地址101 Redwood Shores Parkway

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編94065

電話16506888803

網址https://www.corcept.com/

公司代碼CORT

上市日期Apr 15, 2004

成立日期1998

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-1.34%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

--

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

107.40K

--

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

35.79K

-4.90%

Mr. Atabak Mokari

Chief Financial Officer, Treasurer

14.06K

+7.91%

Mr. Joseph Douglas Lyon

Chief Accounting and Technology Officer

10.07K

--

Mr. William Guyer, Pharm.D.

Chief Development Officer

5.49K

--

Mr. Gregg Huber Alton, J.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-1.34%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

--

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

107.40K

--

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

35.79K

-4.90%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

12.28%

The Vanguard Group, Inc.

9.39%

Ingalls & Snyder LLC (Asset Management)

7.30%

Renaissance Technologies LLC

5.79%

Baker (George Leonard Jr.)

5.01%

Other

60.23%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

12.28%

The Vanguard Group, Inc.

9.39%

Ingalls & Snyder LLC (Asset Management)

7.30%

Renaissance Technologies LLC

5.79%

Baker (George Leonard Jr.)

5.01%

Other

60.23%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

35.90%

Investment Advisor

31.21%

Individual Investor

11.55%

Hedge Fund

8.44%

Research Firm

1.58%

Pension Fund

1.03%

Sovereign Wealth Fund

0.82%

Bank and Trust

0.51%

Family Office

0.06%

Other

8.89%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

722

96.66M

91.15%

-8.10M

2025Q1

746

97.45M

92.10%

-9.12M

2024Q4

673

98.29M

93.20%

-10.89M

2024Q3

625

101.82M

97.42%

-10.51M

2024Q2

589

103.22M

99.09%

-12.69M

2024Q1

582

107.51M

103.94%

+2.98M

2023Q4

555

98.31M

95.40%

-4.22M

2023Q3

540

96.45M

94.14%

-5.68M

2023Q2

523

94.35M

92.83%

-12.18M

2023Q1

528

100.60M

93.30%

-751.20K

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

13.02M

12.28%

-611.02K

-4.48%

Mar 31, 2025

The Vanguard Group, Inc.

9.96M

9.39%

-133.66K

-1.32%

Mar 31, 2025

Ingalls & Snyder LLC (Asset Management)

7.74M

7.3%

-357.16K

-4.41%

Mar 31, 2025

Renaissance Technologies LLC

6.14M

5.79%

-55.57K

-0.90%

Mar 31, 2025

Baker (George Leonard Jr.)

5.31M

5.01%

--

Apr 17, 2025

Parallel Advisors, LLC

3.97M

3.75%

+142.78K

+3.73%

Mar 31, 2025

State Street Global Advisors (US)

3.40M

3.21%

-146.42K

-4.13%

Mar 31, 2025

Belanoff (Joseph K)

2.98M

2.81%

-40.35K

-1.34%

Apr 17, 2025

Wilson (James N)

2.35M

2.21%

+129.14K

+5.82%

Apr 17, 2025

Geode Capital Management, L.L.C.

2.26M

2.13%

+191.89K

+9.28%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

SPDR S&P Pharmaceuticals ETF

5.35%

Invesco S&P SmallCap Health Care ETF

5.17%

Pacer US Small Cap Cash Cows Growth Leaders ETF

4.73%

Formidable ETF

4.13%

Invesco Pharmaceuticals ETF

3.79%

First Trust NYSE Arca Biotechnology Index Fund

3.55%

iShares U.S. Pharmaceuticals ETF

3.46%

Invesco S&P SmallCap Momentum ETF

3.09%

Invesco S&P SmallCap Quality ETF

2.96%

Invesco S&P SmallCap 600 Pure Growth ETF

1.9%

SPDR S&P Pharmaceuticals ETF

佔比5.35%

Invesco S&P SmallCap Health Care ETF

佔比5.17%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比4.73%

Formidable ETF

佔比4.13%

Invesco Pharmaceuticals ETF

佔比3.79%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.55%

iShares U.S. Pharmaceuticals ETF

佔比3.46%

Invesco S&P SmallCap Momentum ETF

佔比3.09%

Invesco S&P SmallCap Quality ETF

佔比2.96%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比1.9%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Corcept Therapeutics Inc

71.880USD

Corcept Therapeutics Inc

71.880

概覽

公司

財務